• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Orally disintegrating selegiline for the treatment of Parkinson's disease.
【24h】

Orally disintegrating selegiline for the treatment of Parkinson's disease.

机译：口服司来吉兰崩解治疗帕金森氏病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The selective monoamine oxidase type B inhibitor selegiline is commonly administered as medical treatment to patients suffering from Parkinson's disease. The clinical value of conventional selegiline is, however, compromised by extensive first-pass metabolism, which reduces its bioavailability and leads to the production of possibly harmful methamfetamine metabolites. This review aims to evaluate a novel, orally disintegrating formulation of selegiline by examining scientific evidence from previous pharmacological and clinical studies. As a result of improved bioavailability, orally disintegrating selegiline can be administered at lower doses than conventional selegiline with similar clinical effect. It also leads to less variable selegiline blood concentrations and produces significantly less methamfetamine metabolites. We conclude that this novel formulation offers an interesting treatment option, especially for patients who report adverse events after initial treatment with conventional selegiline or who suffer from swallowing difficulties.
机译：选择性单胺氧化酶B型抑制剂司来吉兰通常作为药物治疗帕金森氏病患者。但是，常规司来吉兰的临床价值会因广泛的首过代谢而受损，这会降低其生物利用度并导致产生可能有害的甲基苯丙胺代谢产物。这篇综述旨在通过检查来自先前药理和临床研究的科学证据来评估司来吉兰的新型口服崩解制剂。由于改善的生物利用度，可以以比常规司来吉兰更低的剂量给予口服崩解司来吉兰，具有类似的临床效果。它也导致司来吉兰血药浓度变化较小，产生的甲基苯丙胺代谢产物明显减少。我们得出的结论是，这种新型制剂提供了一种有趣的治疗选择，尤其是对于那些在常规司来吉兰初始治疗后报告不良事件或吞咽困难的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号